Lyell Immunopharma (LYEL) Operating Margin: 2020-2025
Historic Operating Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -248,353.33%.
- Lyell Immunopharma's Operating Margin fell 9980922.00% to -248,353.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -836,358.54%, marking a year-over-year decrease of 49172997.00%. This contributed to the annual value of -588,122.95% for FY2024, which is 39811680.00% down from last year.
- As of Q3 2025, Lyell Immunopharma's Operating Margin stood at -248,353.33%, which was up 57.85% from -589,250.00% recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Operating Margin registered a high of -30.55% during Q4 2022, and its lowest value of -2,214,566.67% during Q3 2022.
- Its 3-year average for Operating Margin is -628,854.25%, with a median of -396,369.23% in 2024.
- As far as peak fluctuations go, Lyell Immunopharma's Operating Margin plummeted by 221,278,224bps in 2022, and later soared by 197,841,067bps in 2023.
- Lyell Immunopharma's Operating Margin (Quarterly) stood at -1,684.55% in 2021, then skyrocketed by 165,400bps to -30.55% in 2022, then slumped by 45,772,329bps to -457,753.85% in 2023, then slumped by 137,085,524bps to -1,828,609.09% in 2024, then tumbled by 9,980,922bps to -248,353.33% in 2025.
- Its last three reported values are -248,353.33% in Q3 2025, -589,250.00% for Q2 2025, and -819,528.57% during Q1 2025.